Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome
about
Myo-inositol for preventing gestational diabetesAntenatal dietary supplementation with myo-inositol in women during pregnancy for preventing gestational diabetesInsulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertilityInsulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertilityThe effects of a low-carbohydrate, ketogenic diet on the polycystic ovary syndrome: a pilot studyThe therapy of insulin resistance in other diseases besides type 2 diabetesHow to Achieve High-Quality Oocytes? The Key Role of Myo-Inositol and MelatoninMetabolism and Ovarian Function in PCOS Women: A Therapeutic Approach with InositolsInsulin-Sensitizers, Polycystic Ovary Syndrome and Gynaecological Cancer RiskEffects of Inositol(s) in Women with PCOS: A Systematic Review of Randomized Controlled TrialsInositol Treatment and ART Outcomes in Women with PCOSInositols in the Treatment of Insulin-Mediated DiseasesBroad Spectrum Anticancer Activity of Myo-Inositol and Inositol HexakisphosphateModulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patientsThe menstrual cycle regularization following D-chiro-inositol treatment in PCOS women: a retrospective studyEvaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-Chiro-InositolInositol, glycogen, insulin, and six nobelists.Protection against the synaptic targeting and toxicity of Alzheimer's-associated Aβ oligomers by insulin mimetic chiro-inositols.Determination of urinary Myo-/chiro-inositol ratios from Korean diabetes patients.Polycystic Ovary Syndrome: Insights into the Therapeutic Approach with Inositols.Pharmacotherapy of polycystic ovary syndrome--an update.The metabolic syndrome X.Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome.The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes.Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials.Pretreatment with myo-inositol in non polycystic ovary syndrome patients undergoing multiple follicular stimulation for IVF: a pilot study.myo-Inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study.The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial.D-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review.The polycystic ovary syndrome: treatment with insulin sensitizing agents.Protein modification as oxidative stress marker in follicular fluid from women with polycystic ovary syndrome: the effect of inositol and metformin.Inositols prevent and reverse endothelial dysfunction in diabetic rat and rabbit vasculature metabolically and by scavenging superoxide.The hypoglycemic effect of pumpkin seeds, Trigonelline (TRG), Nicotinic acid (NA), and D-Chiro-inositol (DCI) in controlling glycemic levels in diabetes mellitus.Advances in the treatment of polycystic ovary syndrome.Combining treatment with myo-inositol and D-chiro-inositol (40:1) is effective in restoring ovary function and metabolic balance in PCOS patients.Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials.Enhanced ovarian folliclular development by metformin does not correlate with pregnancy rate: a randomized trial.Insulinoma presenting with hyperandrogenism: a case report and a literature review.Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women With polycystic ovary syndromeA cell factory of Bacillus subtilis engineered for the simple bioconversion of myo-inositol to scyllo-inositol, a potential therapeutic agent for Alzheimer's disease
P2860
Q24186344-011CE723-F781-47E0-B585-16E3CDB08FA1Q24187065-9A5A5F3B-6E71-4118-948E-BAD2946B2030Q24197673-BD1FA080-B3FE-4CF3-827B-0A10B4AA0992Q24240654-6AF71E11-E279-45EB-AD08-3FADF7008E9CQ25257236-7F032CF6-C4AD-4E94-BB64-E37855D6F0BFQ26822399-B632B1E4-37B6-4B61-8ABA-3C1E1E0E6577Q28066892-50CAD69F-4A57-4583-83DB-4E700245DEE5Q28072474-73625D84-2A6C-4550-999E-CAA9EBEC91F2Q28072521-68630FDC-757E-4B3D-8D80-5B31791A9B55Q28073603-AA6F2060-10B3-452B-AD22-AAC8DBA6F255Q28077261-4DFB763E-C17A-4A5E-B719-558FEB2C664BQ28077870-3CD62400-3D2E-49B8-85A0-7A8B5D614BC7Q28078208-9965C116-83D8-4468-9891-24DD1533FE77Q28235398-CE0BA7E5-38A8-4ECE-A3EB-73AA32499FDCQ28248914-526FDBB0-207B-4D5C-9FC6-2896F862C9AEQ28251963-31DD3A39-3D64-4084-B966-9E96E0D5B099Q30413667-3AA2C6D4-F2B1-411F-84F5-19DC13E2B49AQ30415477-D5FCF400-E3FC-4375-A493-743837CC55BCQ33628262-0FF2DB7D-6737-4AC9-A51C-6CA01AE54F48Q33775146-DF4A53C6-5373-4F54-A0A8-301A5A1A65D7Q33787190-1F13C0E9-F98F-4AB1-B45B-78D3D708BB86Q33936947-8D60B894-3653-4DC1-A90F-570DCF0E9CD9Q34018185-29535227-8EA8-43C0-B34D-A0A5A7090057Q34026140-39FBF4DD-5506-4351-BB1E-8863FAE35632Q34030482-FAA53736-C334-4B2D-ACC3-AC2FD380893CQ34032899-5DF3E3BA-8EE0-4A2C-A42D-E429A3304FCCQ34035221-70B255AE-96BA-4B91-9319-BEC5017B67ECQ34036909-DB05C495-D75B-4457-86C1-4F861BA3AFF1Q34153910-9F058D78-2FCB-41D4-B567-456EF4D21C17Q34163132-1FA4A726-069B-4818-89BC-D04D947E128BQ34226362-C29A6A2A-DC33-4E37-BC34-2A65049FDBF2Q34248342-A4A5AE24-C01B-4451-B031-9EC576AB6D6CQ34406395-5C637B7C-13A0-403E-9FB1-A1F54427996FQ34481686-622357AD-73ED-45BE-BC72-0F1D0F477283Q34546109-1AFF1F46-00E9-42EB-B99B-F149B0235BA8Q34557177-905CA080-6DED-44E5-AF74-27B07DDC0ACCQ34661716-56E0209C-2D36-4BA5-A9CA-8A3AD8F77575Q35091013-7F7C167F-3D11-4124-839E-B8B091E9123DQ35117211-0CB56C4A-13EC-40DB-9A52-808528F0178AQ35221716-6A6C669E-1532-4AE4-A987-1230B09DFF16
P2860
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome
description
1999 nî lūn-bûn
@nan
1999 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome
@ast
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome
@en
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome
@nl
type
label
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome
@ast
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome
@en
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome
@nl
prefLabel
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome
@ast
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome
@en
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome
@nl
P2093
P3181
P1476
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome
@en
P2093
P304
P3181
P356
10.1056/NEJM199904293401703
P407
P577
1999-04-29T00:00:00Z